Administration Of Cyclopentolate Research Articles

Effect of topical cyclopentolate alone or combined with phenylephrine in healthy horses.

Evaluate the effect of repeated doses of topical 1% cyclopentolate hydrochloride alone and in combination with topical 2.5% phenylephrine on pupil diameter (PD), tear production (STT-1), intraocular pressure (IOP), digestive function (gut motility and feces production), and heart rate (HR). Six healthy mares. In a prospective, randomized, controlled, and crossover design study, the left eye of six healthy mares was administered 0.2mL of cyclopentolate alone and in combination with 0.2mL of phenylephrine. The drugs were administered 3 times a day for 1day, twice a day for 1day, and then once a day for 2days, as commonly used in practice. Daily and two days after the last topical drug administration, HR, digestive auscultation, feces production, STT-1, IOP, and PD were recorded. The cyclopentolate alone significantly increased the horizontal and vertical PD of the treated eye from day 2 to day 6 (p<.0001) compared with the baseline value. The combination with topical phenylephrine did not have any additional effect on mydriasis compare with the cyclopentolate alone. The other ocular and digestive parameters were not affected by repeated doses of cyclopentolate alone or combined. Repeated administration of cyclopentolate alone or combined with phenylephrine induce a significant mydriasis for at least 48h after the last administration in normal horses' eyes, and do not affect STT-1, IOP, digestive function, and HR. The phenylephrine combined with the cyclopentolate did not potentiate the pupil dilation when compared with cyclopentolate alone in healthy horses.

Infantil delirium induced by cycloplegic eye drops

Cyclopentolate 1% and tropicamide 1% eye drops are considered to be safe in the pediatric population for the fundus examination and treatment of ocular diseases. Although adverse reactions rarely occur, some of them can be life-threatening such as seizure, delirium, coma, arrhythmia, acute life-threatening event, and death. Here we report 15 months old boy who developed delirium after administration of ocular cyclopentolate 1% drops in both eyes during a routine examination for retinopathy of prematurity. Cyclopentolate is a parasympatholytic drug with actions similar to atropine. With ophthalmic administration of cyclopentolate, severe central nervous system effects and systemic reactions may occur. In order to minimize absorption following instill one or two drops of 1% solution, applying pressure to nasolacrimal sac for 2 to 3 min should be considered. In mild to moderate toxicity, benzodiazepines may be used to control central nervous system findings secondary to anticholinergic effects.

The effect of topical administration of cyclopentolate on ocular biometry: An analysis for mouse and human models

Mydriasis with muscarinic antagonists have been used routinely prior to retinal examination and sometimes prior to refractive measurements of the mouse eye. However, biometric changes during topical administration of muscarinic antagonists have not been fully investigated in mice and humans. We found that the mouse eyes treated with cyclopentolate developed a hyperopia with a reduction in both the vitreous chamber depth and axial length. In humans, prior to the cyclopentolate treatment, a 6D accommodative stimulus produced a myopic shift with a reduced anterior chamber depth, choroidal thickness and anterior lens radius of curvature and an increase in lens thickness. After the cyclopentolate treatment, human eyes developed a hyperopic shift with an increased anterior chamber depth and anterior lens radius of curvature and a reduced lens thickness. Therefore, the biometric changes associated with this hyperopic shift were mainly located in the posterior segment of the eye in mice. However, it is the anterior segment of the eye that plays a main role in the hyperopic shift in human subjects. These results further indicate that mouse eyes do not have accommodation which needs to be taken into account when they are used for the study of human refractive errors.

Effect of Cyclopentolate on In Vivo Schlemm Canal Microarchitecture in Healthy Subjects.

To characterize the in vivo effect of cyclopentolate on the microstructure of Schlemm canal (SC) in healthy eyes. For healthy subjects, 81 serial horizontal enhanced depth imaging optical coherence tomography B-scans (interval between scans, ∼35 μm) of the nasal corneoscleral limbal area were obtained before and 1 hour after cyclopentolate 1% administration in 1 eye. The structures of aqueous and blood vessels in each scan were used as landmarks to select 50 overlapping scans between the 2 sets of 81 serial scans (before and after cyclopentolate administration). The SC cross-sectional area was measured in each of the 50 selected scans. After 3-dimensional reconstruction, SC volume was determined. Twelve eyes (12 healthy subjects) were imaged successfully before and after cyclopentolate administration. Mean age was 27.8±4.9 years (range, 25 to 38 y). Following cyclopentolate administration, mean intraocular pressure did not change significantly (13.9±1.5 to 14.2±1.5 mm Hg; P=0.19). Mean SC cross-sectional area decreased by 17%, from 3563±706 to 2959±460 μm (P<0.001). Mean SC volume in the overlapping area (approximately 1.7 mm of circumferential length of SC) decreased from 6,164,061±1,220,787 to 5,119,462±794,763 μm (P<0.001). The decrease in the mean SC cross-sectional area after cyclopentolate administration was greater in eyes with larger baseline SC cross-sectional area (P<0.001, R=0.873). Cyclopentolate causes a reduction in SC dimensions in healthy eyes. Future studies are warranted to determine the exact mechanism(s) of this change.

A Prospective Comparison Between Cyclopentolate Spray and Drops in Pediatric Outpatients

To determine whether children tolerate cyclopentolate 1% spray better than drops and to assess the adequacy of cycloplegia achieved by spray for objective refraction. The effects of cyclopentolate 1% drops and spray on distress levels were assessed prospectively using a guardian questionnaire in consecutive patients 10 years of age or younger. Distress was graded at various points during the appointment using a Likert scale of 1 to 10 (1 = no distress, 10 = severe distress). The adequacy of cycloplegia in children receiving cyclopentolate spray and the waiting times were assessed via a Likert questionnaire completed by the examining physician. The guardians of 72 and 77 children who received cyclopentolate 1% drops or spray, respectively, completed the questionnaire. The children were divided in three age groups: 1 to 4 years, 5 to 7 years, and 8 to 10 years. Children 7 years or younger were significantly less distressed by administration of cyclopentolate 1% spray (P < .005). There was no statistical difference in distress levels in children older than 7 years (P = .9719). Thirteen of the 77 children who received cyclopentolate 1% spray did not have adequate cycloplegia to allow objective refraction. The results demonstrate cyclopentolate 1% spray is less distressing at the time of administration than cyclopentolate 1% drops for children 7 years or younger. However, the cycloplegia achieved is not adequate in a high percentage of children.

Acute progressive midbrain hemorrhage after topical ocular cyclopentolate administration

Cyclopentolate is a synthetic anti-cholinergic agent widely used in ophthalmology clinics. It can cause cardiovascular side-effects such as hypertension, ventricular arrhythmias and tachycardias. A 55-year-old male lost his consciousness after topical cyclopentolate hydrocloride (1%) administration for routine fundoscopic examination in another center. An urgent cranial magnetic resonance imaging examination revealed a midbrain hemorrhage and he was transferred to our hospital. The Glasgow Coma Scale score was at 4 points at admission. The patient was transferred to the intensive care unit and mechanically ventilated. Despite vigorous medical treatment, spontaneous respiration and brainstem reflexes disappeared 12 h after his administration. A control cranial computerized tomography showed enlargement and opening of the hemorrhage into the ventricular system. The patient died on the 12th day of his administration. Systemic side-effects of topical ocular cyclopentolate administration and prevention methods were discussed with regard to the current literature.

Anterior capsule cover and axial movement of intraocular lens

To measure optic shift (OS) of a single piece monofocal intraocular lens (IOL) with varying relationships between anterior capsule cover and IOL optic. This is a prospective randomized masked study of 150 eyes undergoing phacoemulsification. Eyes received either option: 360 degrees total capsule cover (group I); partial cover (group II); or no cover (group III). OS was calculated as difference in anterior chamber depth after administration of cyclopentolate 1% and pilocarpine 2% on IOLMaster at separate visits at 6 months follow-up. Subsequently, using retro-illumination photographs, percentage area of capsule cover was calculated. OS within and between groups I and II was analyzed. The impact of one quartile change in area of capsule cover on percentage change in OS was measured for both groups. Unpaired t-test, correlation, and regression were applied. In groups I, II, and III, mean age of patients was 56.68+/-6.38, 57.09+/-7.34, 59.15+/-6.35 years, respectively; mean OS (mm) was 1.25+/-0.28, 1.20+/-0.24; 0.95+/-0.26 (P=0.013), respectively; and percentage area of capsule cover (%) was 47.35+/-10.48, 33.83+/-10.11, 0.16+/-0.13 (P=0.001), respectively. Mean percentage area of capsule cover in group I vsgroup II was significant (P=0.001). OS was 1.22+/-0.26 mm in groups I and II (combined) vs0.95+/-0.26 mm in group III (P=0.004, (0.06, 0.33)). OS in group I vsgroup II was not significant (P=0.46). Correlation coefficient was r=0.38 (P<0.001). With every increment on quartile (a quartile is any of the three values which divide the sorted data set into four equal parts, so that each part represents one-fourth of the sample or population) class of area of capsule cover the OS increased by 0.12 mm. The OS differed significantly between total and partial cover groups combined vsno cover group.

The Effects of Cyclopentolate on Intraocular Pressure and Retrobulbar Hemodynamics in Patients with Pseudoexfoliation Syndrome and Pseudoexfoliation Glaucoma

Purpose To evaluate the changes of intraocular pressure (IOP) and retrobulbar hemodynamics after cyclopentolate administration in patients with pseudoexfoliation syndrome and pseudoexfoliation glaucoma. Methods Eighteen patients with pseudoexfoliation syndrome and 18 patients with pseudoexfoliation glaucoma were enrolled in the study. After baseline measurements of IOP, the peak systolic velocity (PSV), end-diastolic velocity (EDV), and resistivity index (RI) of the ophthalmic, central retinal, and posterior ciliary arteries were investigated by color Doppler imaging. Then, 1% cyclopentolate was instilled in one eye of each subject. After 45 minutes of instillation of the cyclopentolate, the measurements of IOP and retrobulbar blood flow velocities were repeated. The results were compared with those of 20 age-matched normal subjects. Results Neither IOP nor retrobulbar blood flow velocities changed significantly in control subjects after cyclopentolate administration. IOP increased significantly after cyclopentolate instillation in pseudoexfoliation syndrome (p=0.004). Retrobulbar blood velocities did not change significantly after the cyclopentolate in this group. In pseudoexfoliation glaucoma group, it was observed that basal mean IOP showed a statistically significant increase after cyclopentolate drop (p=0.002). Although blood flow velocities of ophthalmic artery did not change significantly, PSV and EDV of the central retinal and posterior ciliary arteries decreased significantly (p&lt;0.05) and RI of the posterior ciliary artery increased significantly (p=0.01) after cyclopentolate instillation. Conclusions On the basis of our findings, pseudoexfoliation appears to be a predictive factor for an IOP rise after cyclopentolate. In pseudoexfoliation glaucoma patients, an increase of IOP after cyclopentolate could lead to a decreased retrobulbar blood flow. IOP must be rechecked after cyclopentolate administration in these patients to avoid further damage to the ganglion cells.

The effects of cyclopentolate on intraocular pressure and retrobulbar hemodynamics in patients with pseudoexfoliation syndrome and pseudoexfoliation glaucoma.

To evaluate the changes of intraocular pressure (IOP) and retrobulbar hemodynamics after cyclopentolate administration in patients with pseudoexfoliation syndrome and pseudoexfoliation glaucoma. Eighteen patients with pseudoexfoliation syndrome and 18 patients with pseudoexfoliation glaucoma were enrolled in the study. After baseline measurements of IOP, the peak systolic velocity (PSV), end-diastolic velocity (EDV), and resistivity index (RI) of the ophthalmic, central retinal, and posterior ciliary arteries were investigated by color Doppler imaging. Then, 1% cyclopentolate was instilled in one eye of each subject. After 45 minutes of instillation of the cyclopentolate, the measurements of IOP and retrobulbar blood flow velocities were repeated. The results were compared with those of 20 age-matched normal subjects. Neither IOP nor retrobulbar blood flow velocities changed significantly in control subjects after cyclopentolate administration. IOP increased significantly after cyclopentolate instillation in pseudoexfoliation syndrome (p=0.004). Retrobulbar blood velocities did not change significantly after the cyclopentolate in this group. In pseudoexfoliation glaucoma group, it was observed that basal mean IOP showed a statistically significant increase after cyclopentolate drop (p=0.002). Although blood flow velocities of ophthalmic artery did not change significantly, PSV and EDV of the central retinal and posterior ciliary arteries decreased significantly (p<0.05) and RI of the posterior ciliary artery increased significantly (p=0.01) after cyclopentolate instillation. On the basis of our findings, pseudoexfoliation appears to be a predictive factor for an IOP rise after cyclopentolate. In pseudoexfoliation glaucoma patients, an increase of IOP after cyclopentolate could lead to a decreased retrobulbar blood flow. IOP must be rechecked after cyclopentolate administration in these patients to avoid further damage to the ganglion cells. (Eur J Ophthalmol 2004; 14: #-400).

Síndrome confusional agudo por colirio de ciclopentolato

The Acute Confusional State is a process with a multifactorial origin; when reversible, the most fre cuents are due to the deprivation of drugs and the effects of some of them, as the parasympatholiticm agents. These drugs are used in ophtalmology to obtein mydriasis and cycloplegic activity in the t reatment of several cases as well as keratitis or fundus oculi examination. We can not forget that it use as eye drops or ointment can produce systemic side effects. Many of them appair to be dose-re l a ted, and have to be known by the physician who use them. We re p o rt the case of a young women with acute confusional state following the administration of cyclopentolate drops at normal doses. We think it could be interesting, because most of these cases use to happen in children or elderly people or in the case of high doses.

Pseudophakic accommodation? A study of the stability of capsular bag supported, one piece, rigid tripod, or soft flexible implants.

A group of pseudophakic patients was investigated to determine whether their implants shift along an anteroposterior axis under different conditions of ciliary muscle stimulation. There was no statistically significant change in refraction after either pilocarpine or cyclopentolate administration. A change in anterior chamber depth between the position after pilocarpine and that after cyclopentolate was found. It appears that rigid posterior chamber implants do move backwards on ciliary muscle relaxation, but by a maximum 0.25 mm. This is not thought to represent a mechanical threat to ocular health. It is also not enough to account for the apparent accommodative ability of some pseudophakic patients. The possible causes for this phenomenon are discussed.